Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs

References

• Lolli F, Pallotti F, Rossi A, et al. Androgenetic alopecia: a review. Endocrine. 2017;57(1):9–17. doi:10.1007/s12020-017-1280-y
   PubMed Web of Science ®Google Scholar
• Price VH. Androgenetic alopecia in women. J Investig Dermatol Symp Proc. 2003;8(1):24–27. doi:10.1046/j.1523-1747.2003.12168.x
   PubMedGoogle Scholar
• Trüeb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol. 2002;37(8–9):981–990. doi:10.1016/S0531-5565(02)00093-1
   PubMed Web of Science ®Google Scholar
• Kaliyadan F, Nambiar A, Vijayaraghavan S. Androgenetic alopecia: an update. Indian J Dermatol Venereol Leprol. 2013;79(5):613. doi:10.4103/0378-6323.116730
   PubMed Web of Science ®Google Scholar
• Ho CH, Sood T, Zito PM. Androgenetic alopecia. In: StatPearls. StatPearls Publishing; 2021.
   Google Scholar
• Rathnayake D, Sinclair R. Male androgenetic alopecia. Expert Opin Pharmacother. 2010;11(8):1295–1304. doi:10.1517/14656561003752730
   PubMed Web of Science ®Google Scholar
• Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev Mol Med. 2002;4(22):1–11. doi:10.1017/S1462399402005112
   Google Scholar
• Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136–141. e5. doi:10.1016/j.jaad.2017.02.054
   PubMed Web of Science ®Google Scholar
• Zins GR. The history of the development of minoxidil. Clin Dermatol. 1988;6(4):132–147. doi:10.1016/0738-081X(88)90078-8
   PubMed Web of Science ®Google Scholar
• Randolph M, Tosti A. Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2021;84(3):737–746. doi:10.1016/j.jaad.2020.06.1009
   PubMedGoogle Scholar
• Barnett AC, Tsvetanov S, Gamage N, et al. Active site mutations and substrate inhibition in human sulfotransferase 1A1 and 1A3. J Biol Chem. 2004;279(18):18799–18805. doi:10.1074/jbc.M312253200
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777. doi:10.2147/DDDT.S214907
   PubMed Web of Science ®Google Scholar
• Gupta A, Talukder M, Venkataraman M, et al. Minoxidil: a comprehensive review. J DermatolTreat. 2022;33(4):1896–1906. doi:10.1080/09546634.2021.1945527
   Google Scholar
• Pekmezci E, Turkoğlu M, Gökalp H, et al. Minoxidil downregulates interleukin-1 alpha gene expression in HaCaT cells. Int J Trichology. 2018;10(3):108. doi:10.4103/ijt.ijt_18_17
   PubMedGoogle Scholar
• Kvedar JC, Baden HP, Levine L. Selective inhibition by minoxidil of prostacyclin production by cells in culture. Biochem Pharmacol. 1988;37(5):867–874. doi:10.1016/0006-2952(88)90174-8
   PubMed Web of Science ®Google Scholar
• Kwack MH, Kang BM, Kim MK, et al. Minoxidil activates β-catenin pathway in human dermal papilla cells: a possible explanation for its anagen prolongation effect. J Dermatol Sci. 2011;62(3):154–159. doi:10.1016/j.jdermsci.2011.01.013
   PubMed Web of Science ®Google Scholar
• Kelly Y, Blanco A, Tosti A. Androgenetic alopecia: an update of treatment options. Drugs. 2016;76(14):1349–1364. doi:10.1007/s40265-016-0629-5
   PubMed Web of Science ®Google Scholar
• Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377–385. doi:10.1067/mjd.2002.124088
   PubMed Web of Science ®Google Scholar
• Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541–553. doi:10.1016/j.jaad.2003.06.014
   PubMed Web of Science ®Google Scholar
• Blumeyer A, Tosti A, Messenger A, et al. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men. JDDG. 2011;9:S1–S57. doi:10.1111/j.1610-0379.2011.07802.x
   Google Scholar
• Goren A, Shapiro J, Roberts J, et al. Clinical utility and validity of minoxidil response testing in androgenetic alopecia. Dermatol Ther. 2015;28(1):13–16. doi:10.1111/dth.12164
   PubMed Web of Science ®Google Scholar
• Messenger A, Rundegren J. Minoxidil: mechanisms of action on hair growth. BrJ Dermatol. 2004;150(2):186–194. doi:10.1111/j.1365-2133.2004.05785.x
   PubMed Web of Science ®Google Scholar
• Olsen EA, Weiner MS, Amara IA, et al. Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. J Am Acad Dermatol. 1990;22(4):643–646. doi:10.1016/0190-9622(90)70089-Z
   PubMed Web of Science ®Google Scholar
• Goren A, Castano JA, McCoy J, et al. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatol Ther. 2013;27(3):171–173. doi:10.1111/dth.12111
   PubMed Web of Science ®Google Scholar
• Roberts J, Desai N, McCoy J, et al. Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia. Dermatol Ther. 2014;27(4):252–254. doi:10.1111/dth.12130
   PubMed Web of Science ®Google Scholar
• Munck A, Gavazzoni MF, Trüeb RM. Use of low-level laser therapy as monotherapy or concomitant therapy for male and female androgenetic alopecia. Int J Trichology. 2014;6(2):45. doi:10.4103/0974-7753.138584
   PubMedGoogle Scholar
• Qiu J, Yi Y, Jiang L, et al. Efficacy assessment for low-level laser therapy in the treatment of androgenetic alopecia: a real-world study on 1383 patients. Lasers Med Sci. 2022;37:1–6.
   Web of Science ®Google Scholar
• Gkini M-A, Kouskoukis AE, Tripsianis G, et al. Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period. J Cutan Aesthet Surg. 2014;7(4):213. doi:10.4103/0974-2077.150743
   PubMedGoogle Scholar
• Singhal P, Agarwal S, Dhot P, et al. Efficacy of platelet-rich plasma in treatment of androgenic alopecia. Asian J Transfus Sci. 2015;9(2):159. doi:10.4103/0973-6247.162713
   PubMedGoogle Scholar
• Verma K, Tegta G, Verma G, et al. A study to compare the efficacy of platelet-rich plasma and minoxidil therapy for the treatment of androgenetic alopecia. Int J Trichology. 2019;11(2):68. doi:10.4103/ijt.ijt_64_18
   PubMedGoogle Scholar
• Dhurat R, Sukesh MS, Avhad G, et al. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichology. 2013;5(1):6. doi:10.4103/0974-7753.114700
   PubMedGoogle Scholar
• Starace M, Alessandrini A, Brandi N, et al. Preliminary results of the use of scalp microneedling in different types of alopecia. J Cosmet Dermatol. 2020;19(3):646–650. doi:10.1111/jocd.13061
   PubMed Web of Science ®Google Scholar
• Mori O, Uno H. The effect of topical minoxidil on hair follicular cycles of rats. J Dermatol. 1990;17(5):276–281. doi:10.1111/j.1346-8138.1990.tb01641.x
   PubMedGoogle Scholar
• Panchaprateep R, Lueangarun S. Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: an open-label and global photographic assessment. Dermatol Ther. 2020;10:1345–1357. doi:10.1007/s13555-020-00448-x
   PubMed Web of Science ®Google Scholar
• Andy G, John M, Mirna S, et al. Controversies in the treatment of androgenetic alopecia: the history of finasteride. Dermatol Ther. 2019;32(2):e12647. doi:10.1111/dth.12647
   PubMed Web of Science ®Google Scholar
• Libecco JF, Bergfeld WF. Finasteride in the treatment of alopecia. Expert Opin Pharmacother. 2004;5(4):933–940. doi:10.1517/14656566.5.4.933
   PubMed Web of Science ®Google Scholar
• Rossi A, Cantisani C, Scarnò M, et al. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10‐year follow‐up. Dermatol Ther. 2011;24(4):455–461. doi:10.1111/j.1529-8019.2011.01441.x
   PubMed Web of Science ®Google Scholar
• Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4):578–589. doi:10.1016/S0190-9622(98)70007-6
   PubMed Web of Science ®Google Scholar
• Mella JM, Perret MC, Manzotti M, et al. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010;146(10):1141–1150. doi:10.1001/archdermatol.2010.256
   PubMed Web of Science ®Google Scholar
• Yoshitake T, Takeda A, Ohki K, et al. Five‐year efficacy of finasteride in 801 Japanese men with androgenetic alopecia. J Dermatol. 2015;42(7):735–738. doi:10.1111/1346-8138.12890
   PubMed Web of Science ®Google Scholar
• Shin JW, Chung E-H, Kim M-B, et al. Evaluation of long‐term efficacy of finasteride in Korean men with androgenetic alopecia using the basic and specific classification system. J Dermatol. 2019;46(2):139–143. doi:10.1111/1346-8138.14719
   PubMed Web of Science ®Google Scholar
• Thai KE, Sinclair R. Finasteride for female androgenetic alopecia. Br J Dermatol. 2002;147(4):812–813. doi:10.1046/j.1365-2133.2002.49084.x
   PubMed Web of Science ®Google Scholar
• Hu AC, Chapman LW, Mesinkovska NA. The efficacy and use of finasteride in women: a systematic review. Int J Dermatol. 2019;58(7):759–776. doi:10.1111/ijd.14370
   PubMed Web of Science ®Google Scholar
• Hirshburg JM, Kelsey PA, Therrien CA, et al. Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic review. J Clin Aesthet Dermatol. 2016;9(7):56.
   PubMedGoogle Scholar
• Ganzer CA, Jacobs AR, Iqbal F. Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms. Am J Men Health. 2015;9(3):222–228. doi:10.1177/1557988314538445
   PubMed Web of Science ®Google Scholar
• Wang L, Lei Y, Gao Y, et al. Association of finasteride with prostate cancer: a systematic review and meta-analysis. Medicine. 2020;99:15.
   Web of Science ®Google Scholar
• Villani A, Fabbrocini G, Ocampo‐Candiani J, et al. Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose. J Eur Acad Dermatol Venereol. 2021;35(7):1485–1492. doi:10.1111/jdv.17216
   PubMed Web of Science ®Google Scholar
• Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R, et al. Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. J Am Acad Dermatol. 2019;81(2):648–649. doi:10.1016/j.jaad.2019.04.054
   PubMed Web of Science ®Google Scholar
• Ramos P, Goren A, Sinclair R, et al. Oral minoxidil bio‐activation by hair follicle outer root sheath cell sulfotransferase enzymes predicts clinical efficacy in female pattern hair loss. J Eur Acad Dermatol Venereol. 2020;34(1):e40–e41. doi:10.1111/jdv.15891
   PubMed Web of Science ®Google Scholar
• Beach RA. Case series of oral minoxidil for androgenetic and traction alopecia: tolerability & the five C’s of oral therapy. Dermatol Ther. 2018;31(6):e12707. doi:10.1111/dth.12707
   PubMed Web of Science ®Google Scholar
• Ramos PM, Sinclair RD, Kasprzak M, et al. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: a randomized clinical trial. J Am Acad Dermatol. 2020;82(1):252–253. doi:10.1016/j.jaad.2019.08.060
   PubMed Web of Science ®Google Scholar
• Vastarella M, Cantelli M, Patrì A, et al. Efficacy and safety of oral minoxidil in female androgenetic alopecia. Dermatol Ther. 2020;33(6). doi:10.1111/dth.14234
   Web of Science ®Google Scholar
• Jimenez-Cauhe J, Saceda-Corralo D, Moreno-Arrones OM, et al. Reply to: “Very-low-dose oral minoxidil in male androgenetic alopecia: a study with quantitative trichoscopic documentation”. J Am Acad Dermatol. 2020;82(1):e23–e24. doi:10.1016/j.jaad.2019.08.085
   PubMed Web of Science ®Google Scholar
• Sanabria B, Vanzela TDN, Miot HA, et al. Adverse effects of low-dose oral minoxidil for androgenetic alopecia in 435 patients. J Am Acad Dermatol. 2021;84(4):1175–1178. doi:10.1016/j.jaad.2020.11.035
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Iamsumang W, Leerunyakul K. Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. J DermatolTreat. 2022;33(2):643–648. doi:10.1080/09546634.2020.1782324
   Google Scholar
• Caserini M, Radicioni M, Leuratti C, et al. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014;52(10):842–849. doi:10.5414/CP202119
   PubMed Web of Science ®Google Scholar
• Piraccini B, Blume‐Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a Phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022;36(2):286–294. doi:10.1111/jdv.17738
   PubMed Web of Science ®Google Scholar
• Hajheydari Z, Akbari J, Saeedi M, et al. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2009;75(1):47. doi:10.4103/0378-6323.45220
   PubMed Web of Science ®Google Scholar
• Gupta AK, Talukder M. Topical finasteride for male and female pattern hair loss: is it a safe and effective alternative? J Cosmet Dermatol. 2022;21(5):1841–1848. doi:10.1111/jocd.14895
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Srisuwanwattana P, Chalermroj N, et al. A randomized, double‐blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018;32(12):2257–2263. doi:10.1111/jdv.15171
   PubMed Web of Science ®Google Scholar
• Chandrashekar B, Nandhini T, Vasanth V, et al. Topical minoxidil fortified with finasteride: an account of maintenance of hair density after replacing oral finasteride. Indian Dermatol Online J. 2015;6(1):17. doi:10.4103/2229-5178.148925
   PubMedGoogle Scholar
• Rai PB, Khushwaha P, Jain N, et al. Comparing the therapeutic efficacy of topical minoxidil and finasteride with topical minoxidil and oral finasteride in androgenetic alopecia: a randomized trial. Int J Res Dermatol. 2018;4(3):386–390. doi:10.18203/issn.2455-4529.IntJResDermatol20183163
   Google Scholar
• Tsunemi Y, Irisawa R, Yoshiie H, et al. Long‐term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. J Dermatol. 2016;43(9):1051–1058. doi:10.1111/1346-8138.13310
   PubMed Web of Science ®Google Scholar
• Harcha WG, Barboza Martínez J, Tsai T-F, et al. A randomized, active-and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489–498. e3. doi:10.1016/j.jaad.2013.10.049
   PubMed Web of Science ®Google Scholar
• Jung JY, Yeon JH, Choi JW, et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol. 2014;53(11):1351–1357. doi:10.1111/ijd.12060
   PubMed Web of Science ®Google Scholar
• Gupta AK, Foley KA. A critical assessment of the evidence for low-level laser therapy in the treatment of hair loss. Dermatol Surg. 2017;43(2):188–197. doi:10.1097/DSS.0000000000000904
   PubMed Web of Science ®Google Scholar
• Avci P, Gupta A, Sadasivam M, et al. Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. In: Seminars in Cutaneous Medicine and Surgery. NIH Public Access; 2013.
   Google Scholar
• Friedman S, Schnoor P. Novel approach to treating androgenetic alopecia in females with photobiomodulation (low-level laser therapy). Dermatol Surg. 2017;43(6):856–867. doi:10.1097/DSS.0000000000001114
   PubMed Web of Science ®Google Scholar
• Kaiser MA, Almeida SM, Rodriguez M, et al. Low-level light therapy and minoxidil combination treatment in androgenetic alopecia: a review of the literature. Skin Appendage Disord. 2023;9(2):1–7. doi:10.1159/000527782
   PubMed Web of Science ®Google Scholar
• Egger A, Resnik SR, Aickara D, et al. Examining the safety and efficacy of low-level laser therapy for male and female pattern hair loss: a review of the literature. Skin Appendage Dis. 2020;6(5):259–267. doi:10.1159/000509001
   PubMed Web of Science ®Google Scholar
• Avci P, Gupta GK, Clark J, et al. Low‐level laser (light) therapy (LLLT) for treatment of hair loss. Lasers Surg Med. 2014;46(2):144–151. doi:10.1002/lsm.22170
   PubMed Web of Science ®Google Scholar
• Wikramanayake TC, Rodriguez R, Choudhary S, et al. Effects of the Lexington LaserComb on hair regrowth in the C3H/HeJ mouse model of alopecia areata. Lasers Med Sci. 2012;27(2):431–436. doi:10.1007/s10103-011-0953-7
   PubMed Web of Science ®Google Scholar
• Liu K-H, Liu D, Chen Y-T, et al. Comparative effectiveness of low-level laser therapy for adult androgenic alopecia: a system review and meta-analysis of randomized controlled trials. Lasers Med Sci. 2019;34(6):1063–1069. doi:10.1007/s10103-019-02723-6
   PubMed Web of Science ®Google Scholar
• Afifi L, Maranda EL, Zarei M, et al. Low‐level laser therapy as a treatment for androgenetic alopecia. Lasers Surg Med. 2017;49(1):27–39. doi:10.1002/lsm.22512
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Chalermroj N, Khunkhet S. Low-level laser therapy for the treatment of androgenetic alopecia in Thai men and women: a 24-week, randomized, double-blind, sham device-controlled trial. Lasers Med Sci. 2019;34(6):1107–1114. doi:10.1007/s10103-018-02699-9
   PubMed Web of Science ®Google Scholar
• Esmat SM, Hegazy RA, Gawdat HI, et al. Low level light‐minoxidil 5% combination versus either therapeutic modality alone in management of female patterned hair loss: a randomized controlled study. Lasers Surg Med. 2017;49(9):835–843. doi:10.1002/lsm.22684
   PubMed Web of Science ®Google Scholar
• Zhou Y, Chen C, Qu Q, et al. The effectiveness of combination therapies for androgenetic alopecia: a systematic review and meta‐analysis. Dermatol Ther. 2020;33(4):e13741. doi:10.1111/dth.13741
   PubMed Web of Science ®Google Scholar
• Foster TE, Puskas BL, Mandelbaum BR, et al. Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 2009;37(11):2259–2272. doi:10.1177/0363546509349921
   PubMed Web of Science ®Google Scholar
• Hesseler MJ, Shyam N. Platelet-rich plasma and its utility in medical dermatology: a systematic review. J Am Acad Dermatol. 2019;81(3):834–846. doi:10.1016/j.jaad.2019.04.037
   PubMed Web of Science ®Google Scholar
• Emer J. Platelet-rich plasma (PRP): current applications in dermatology. Skin Therapy Lett. 2019;24(5):1–6.
   PubMedGoogle Scholar
• Leo MS, Kumar AS, Kirit R, et al. Systematic review of the use of platelet‐rich plasma in aesthetic dermatology. J Cosmet Dermatol. 2015;14(4):315–323. doi:10.1111/jocd.12167
   PubMed Web of Science ®Google Scholar
• Gupta AK, Carviel J. A mechanistic model of platelet-rich plasma treatment for androgenetic alopecia. Dermatol Surg. 2016;42(12):1335–1339. doi:10.1097/DSS.0000000000000901
   PubMed Web of Science ®Google Scholar
• Gupta AK, Cole J, Deutsch DP, et al. Platelet-rich plasma as a treatment for androgenetic alopecia. Dermatol Surg. 2019;45(10):1262–1273. doi:10.1097/DSS.0000000000001894
   PubMed Web of Science ®Google Scholar
• Giordano S, Romeo M, Lankinen P. Platelet‐rich plasma for androgenetic alopecia: does it work? Evidence from meta analysis. J Cosmet Dermatol. 2017;16(3):374–381. doi:10.1111/jocd.12331
   PubMed Web of Science ®Google Scholar
• Dashore S, Chouhan K, Nanda S, et al. Preparation of platelet-rich plasma: national IADVL PRP taskforce recommendations. Indian Dermatol Online J. 2021;12(Suppl 1):S12. doi:10.4103/idoj.idoj_269_21
   PubMedGoogle Scholar
• Singh A, Yadav S. Microneedling: advances and widening horizons. Indian Dermatol Online J. 2016;7:4.
   Google Scholar
• Kim YS, Jeong KH, Kim JE, et al. Repeated microneedle stimulation induces enhanced hair growth in a murine model. Ann Dermatol. 2016;28(5):586. doi:10.5021/ad.2016.28.5.586
   PubMed Web of Science ®Google Scholar
• Liebl H, Kloth LC. Skin cell proliferation stimulated by microneedles. J Am Coll Clin Wound Spec. 2012;4(1):2–6. doi:10.1016/j.jccw.2012.11.001
   PubMedGoogle Scholar
• Gowda BJ, Ahmed MG, Sanjana A. Can microneedles replace hypodermic needles? Painless drug delivery. Resonance. 2022;27(1):63–85. doi:10.1007/s12045-022-1294-5
   Google Scholar
• Gowda BJ, Ahmed MG, Hani U, et al. Microneedles as a momentous platform for psoriasis therapy and diagnosis: a state-of-The-art review. Int J Pharm. 2023;632:122591. doi:10.1016/j.ijpharm.2023.122591
   PubMedGoogle Scholar
• Katzer T, Leite Junior A, Beck R, et al. Physiopathology and current treatments of androgenetic alopecia: going beyond androgens and anti-androgens. Dermatol Ther. 2019;32(5). doi:10.1111/dth.13059
   PubMed Web of Science ®Google Scholar
• Doddaballapur S. Microneedling with dermaroller. J Cutan Aesthet Surg. 2009;2(2):110. doi:10.4103/0974-2077.58529
   PubMedGoogle Scholar
• Jha AK, Vinay K. Androgenetic alopecia and microneedling: every needling is not microneedling. J Am Acad Dermatol. 2019;81(2):e43–e44. doi:10.1016/j.jaad.2019.02.070
   PubMed Web of Science ®Google Scholar
• Jha AK, Udayan UK, Roy PK, et al. Original article: platelet-rich plasma with microneedling in androgenetic alopecia along with dermoscopic pre- and post-treatment evaluation. J Cosmet Dermatol. 2018;17(3):313–318. doi:10.1111/jocd.12394
   PubMed Web of Science ®Google Scholar
• Shah KB, Shah AN, Solanki RB, et al. A comparative study of microneedling with platelet-rich plasma plus topical minoxidil (5%) and topical minoxidil (5%) alone in androgenetic alopecia. Int J Trichology. 2017;9(1):14. doi:10.4103/ijt.ijt_75_16
   PubMedGoogle Scholar
• Dhurat R, Sukesh M. Response to microneedling treatment in men with androgenetic alopecia who failed to respond to conventional therapy. Indian J Dermatol. 2015;60(3):260. doi:10.4103/0019-5154.156361
   PubMed Web of Science ®Google Scholar
• Lee YB, Eun YS, Lee JH, et al. Effects of topical application of growth factors followed by microneedle therapy in women with female pattern hair loss: a pilot study. J Dermatol. 2013;40(1):81–83. doi:10.1111/j.1346-8138.2012.01680.x
   PubMed Web of Science ®Google Scholar
• Alves R, Grimalt R. Platelet-rich plasma in combination with 5% minoxidil topical solution and 1 mg oral finasteride for the treatment of androgenetic alopecia: a randomized placebo-controlled, double-blind, half-head study. Dermatol Surg. 2018;44(1):126–130. doi:10.1097/DSS.0000000000001198
   PubMed Web of Science ®Google Scholar
• Pakhomova EE, Smirnova IO. Comparative evaluation of the clinical efficacy of prp-therapy, minoxidil, and their combination with immunohistochemical study of the dynamics of cell proliferation in the treatment of men with androgenetic alopecia. Int J Mol Sci. 2020;21(18):6516. doi:10.3390/ijms21186516
   PubMed Web of Science ®Google Scholar
• Singh S, Kumar V, Rai T. Comparison of efficacy of platelet-rich plasma therapy with or without topical 5% minoxidil in male-type baldness: a randomized, double-blind placebo control trial. Indian J Dermatol Venereol Leprol. 2020;86(2):150–157. doi:10.4103/ijdvl.IJDVL_589_18
   PubMed Web of Science ®Google Scholar
• Ramadan WM, Hassan AM, Ismail MA, et al. Evaluation of adding platelet‐rich plasma to combined medical therapy in androgenetic alopecia. J Cosmet Dermatol. 2021;20(5):1427–1434. doi:10.1111/jocd.13935
   PubMed Web of Science ®Google Scholar
• Ray R, Sharma A. Comparison of 5% minoxidil lotion monotherapy versus its combination with autologous platelet rich plasma in androgenetic alopecia in hundred males. Med J Armed Forces India. 2021;77(3):355–362. doi:10.1016/j.mjafi.2020.11.010
   PubMedGoogle Scholar
• Gentile P, Dionisi L, Pizzicannella J, et al. A randomized blinded retrospective study: the combined use of micro-needling technique, low-level laser therapy and autologous non-activated platelet-rich plasma improves hair re-growth in patients with androgenic alopecia. Expert Opin Biol Ther. 2020;20(9):1099–1109. doi:10.1080/14712598.2020.1797676
   PubMed Web of Science ®Google Scholar
• Yepuri V, Venkataram M. Platelet-rich plasma with microneedling in androgenetic alopecia: study of efficacy of the treatment and the number of sessions required. J Cutan Aesthet Surg. 2021;14(2):184. doi:10.4103/JCAS.JCAS_33_20
   PubMedGoogle Scholar
• Jha AK, Vinay K, Zeeshan M, et al. Platelet‐rich plasma and microneedling improves hair growth in patients of androgenetic alopecia when used as an adjuvant to minoxidil. J Cosmet Dermatol. 2019;18(5):1330–1335. doi:10.1111/jocd.12864
   PubMed Web of Science ®Google Scholar
• Aggarwal K, Gupta S, Jangra R, et al. Dermoscopic assessment of microneedling alone versus microneedling with platelet-rich plasma in cases of male pattern alopecia: a split-head comparative study. Int J Trichology. 2020;12(4):156. doi:10.4103/ijt.ijt_64_20
   PubMedGoogle Scholar
• Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low‐dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104–109. doi:10.1111/ijd.13838
   PubMed Web of Science ®Google Scholar
• Carone L, Oxberry SG, Twycross R, et al. Spironolactone. J Pain Symptom Manage. 2017;53(2):288–292. doi:10.1016/j.jpainsymman.2016.12.320
   PubMed Web of Science ®Google Scholar
• Goodfellow A, ALAGHBAND-ZADEH J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol. 1984;111(2):209–214. doi:10.1111/j.1365-2133.1984.tb04045.x
   PubMed Web of Science ®Google Scholar
• Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin. 2010;28(3):611–618. doi:10.1016/j.det.2010.03.011
   PubMed Web of Science ®Google Scholar
• James JF, Jamerson TA, Aguh C. Efficacy and safety profile of oral spironolactone use for androgenic alopecia—a systematic review. J Am Acad Dermatol. 2021;2021:1.
   Google Scholar
• Hussein SM, Soliman AM, Abd El-Alim SH, et al. Assessment of the efficacy of topical antiandrogen; spironolactone in patients with androgenetic alopecia by dermoscopy. J Pak Assoc Dermatol. 2022;32(3):493–501.
   Google Scholar
• Burns LJ, De Souza B, Flynn E, et al. Spironolactone for treatment of female pattern hair loss. J Am Acad Dermatol. 2020;83(1):276–278. doi:10.1016/j.jaad.2020.03.087
   PubMed Web of Science ®Google Scholar
• Famenini S, Slaught C, Duan L, et al. Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy. J Am Acad Dermatol. 2015;73(4):705–706. doi:10.1016/j.jaad.2015.06.063
   PubMed Web of Science ®Google Scholar
• Ahmed SA, Ayman EY, Mousa A. Topical finasteride versus topical spironolactone in the treatment of androgenetic alopecia. Med J Cairo Univ. 2020;88:1017–1022. doi:10.21608/mjcu.2020.110836
   Google Scholar
• Ammar AM, Elshahid AR, Abdel‐Dayem HA, et al. Dermoscopic evaluation of the efficacy of combination of topical spironolactone 5% and minoxidil 5% solutions in the treatment of androgenetic alopecia: a cross sectional‐comparative study. J Cosmet Dermatol. 2022;21(11):5790–5799. doi:10.1111/jocd.15328
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang H, Zheng Q, et al. Botulinum toxin as a double‐edged sword in alopecia: a systematic review. J Cosmet Dermatol. 2020;19(10):2560–2565. doi:10.1111/jocd.13647
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yu S, Zhao J, et al. Effectiveness and safety of botulinum toxin type A in the treatment of androgenetic alopecia. Biomed Res Int. 2020;2020:1–7. doi:10.1155/2020/1501893
   Web of Science ®Google Scholar
• Carloni R, Pechevy L, Postel F, et al. Is there a therapeutic effect of botulinum toxin on scalp alopecia? Physiopathology and reported cases: a systematic review of the literature. J Plast Reconstr Aesthet Surg. 2020;73(12):2210–2216. doi:10.1016/j.bjps.2020.05.035
   PubMed Web of Science ®Google Scholar
• Zhang L, Yu Q, Wang Y, et al. A small dose of botulinum toxin A is effective for treating androgenetic alopecia in Chinese patients. Dermatol Ther. 2019;32(4):e12785. doi:10.1111/dth.12785
   PubMed Web of Science ®Google Scholar
• Freund BJ, Schwartz M. Treatment of male pattern baldness with botulinum toxin: a pilot study. Plast Reconstr Surg. 2010;126(5):246e–248e. doi:10.1097/PRS.0b013e3181ef816d
   PubMed Web of Science ®Google Scholar
• Shon U, Kim MH, Lee DY, et al. The effect of intradermal botulinum toxin on androgenetic alopecia and its possible mechanism. J Am Acad Dermatol. 2020;83(6):1838–1839. doi:10.1016/j.jaad.2020.04.082
   PubMed Web of Science ®Google Scholar
• Cho HR, Lew B-L, Lew H, et al. Treatment effects of intradermal botulinum toxin type A injection on alopecia areata. Dermatol Surg. 2010;36:2175–2181. doi:10.1111/j.1524-4725.2010.01709.x
   PubMed Web of Science ®Google Scholar
• English RS, Ruiz S. Use of botulinum toxin for androgenic alopecia: a systematic review. Skin Appendage Dis. 2022;2022:1–8.
   Google Scholar
• Kowing D. Madarosis and facial alopecia presumed secondary to botulinum a toxin injections. Optom Vision Sci. 2005;82(7):579–582. doi:10.1097/01.opx.0000171332.53664.df
   PubMed Web of Science ®Google Scholar
• Di Pietro A, Piraccini BM. Frontal alopecia after repeated botulinum toxin type A injections for forehead wrinkles: an underestimated entity? Skin Appendage Disord. 2016;2(1–2):67–69. doi:10.1159/000448380
   PubMedGoogle Scholar
• Gentile P, Garcovich S. Advances in regenerative stem cell therapy in androgenic alopecia and hair loss: wnt pathway, growth-factor, and mesenchymal stem cell signaling impact analysis on cell growth and hair follicle development. Cells. 2019;8(5):466. doi:10.3390/cells8050466
   PubMed Web of Science ®Google Scholar
• Talavera-Adame D, Newman D, Newman N. Conventional and novel stem cell based therapies for androgenic alopecia. Stem Cells Cloning. 2017;10:11. doi:10.2147/SCCAA.S138150
   PubMed Web of Science ®Google Scholar
• Leiros GJ, Attorresi AI, Balaña ME. Hair follicle stem cell differentiation is inhibited through cross‐talk between Wnt/β‐catenin and androgen signalling in dermal papilla cells from patients with androgenetic alopecia. Br J Dermatol. 2012;166(5):1035–1042. doi:10.1111/j.1365-2133.2012.10856.x
   PubMed Web of Science ®Google Scholar
• Elmaadawi IH, Mohamed BM, Ibrahim ZAS, et al. Stem cell therapy as a novel therapeutic intervention for resistant cases of alopecia areata and androgenetic alopecia. J DermatolTreat. 2018;29(5):431–440. doi:10.1080/09546634.2016.1227419
   Google Scholar
• Tak YJ, Lee SY, Cho AR, et al. A randomized, double-blind, vehicle-controlled clinical study of hair regeneration using adipose-derived stem cell constituent extract in androgenetic alopecia. Stem Cells Transl Med. 2020;9(8):839–849. doi:10.1002/sctm.19-0410
   PubMed Web of Science ®Google Scholar
• Zari S. Short-term efficacy of autologous cellular micrografts in male and female androgenetic alopecia: a retrospective cohort study. Clin Cosmet Investig Dermatol. 2021;Volume 14:1725–1736. doi:10.2147/CCID.S334807
   Web of Science ®Google Scholar
• Drake L, Drake L, Han JJ, et al. Evaluation of the safety and effectiveness of nutritional supplements for treating hair loss: a systematic review. JAMA Dermatol. 2022;158(10):1187–1191. doi:10.1001/jamadermatol.2022.3025
   PubMedGoogle Scholar
• Sun H, Sebaratnam D. Clascoterone as a novel treatment for androgenetic alopecia. Clin Exp Dermatol. 2020;45(7):913–914. doi:10.1111/ced.14292
   PubMed Web of Science ®Google Scholar
• Nestor MS, Ablon G, Gade A, et al. Treatment options for androgenetic alopecia: efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021;20(12):3759–3781. doi:10.1111/jocd.14537
   PubMed Web of Science ®Google Scholar
• Rosette C, Rosette N, Mazzetti A, et al. Cortexolone 17α-propionate (clascoterone) is an androgen receptor antagonist in dermal papilla cells in vitro. J Drugs Dermatol. 2019;18(2):197–201.
   PubMed Web of Science ®Google Scholar
• Kanti V, Messenger A, Dobos G, et al. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men–short version. J Eur Acad Dermatol Venereol. 2018;32(1):11–22. doi:10.1111/jdv.14624
   PubMed Web of Science ®Google Scholar